Journal of Microbiology and Biotechnology

The Korean Society for Microbiology and Biotechnology (한국미생물·생명공학회)
권호 표지
DOI QR코드

DOI QR Code

Serum Levels and Glycosylation Changes of Alpha-1-Acid Glycoprotein According to Severity of Breast Cancer in Korean Women

  • Choi, Jae Woong (Laboratory of Virology, College of Pharmacy, Chung-Ang University) ;
  • Jeong, Ki-Ho (Laboratory of Virology, College of Pharmacy, Chung-Ang University) ;
  • You, Ji Won (Laboratory of Virology, College of Pharmacy, Chung-Ang University) ;
  • Lee, Jun Woo (Breast and Thyroid Cancer Center, Ewha Womans University Cancer Center for Women) ;
  • Moon, Byung-In (Breast and Thyroid Cancer Center, Ewha Womans University Cancer Center for Women) ;
  • Kim, Hyoung Jin (Laboratory of Virology, College of Pharmacy, Chung-Ang University) ;
  • Kim, Hong-Jin (Laboratory of Virology, College of Pharmacy, Chung-Ang University)
  • Received : 2020.06.04
  • Accepted : 2020.06.11
  • Published : 2020.09.28
Download PDF
⟨ Previous Next ⟩

Abstract

Elevated serum levels of alpha-1-acid glycoprotein (AGP) are known to be associated with several types of cancer. In addition, some reports have indicated that changes in glycosylation of AGP are associated with cancer progression. However, changes in AGP levels of serum and changes in glycosylation of AGPs in breast cancer have not been specifically studied. In the present study, serum AGP levels in benign (BN) cancer and breast cancer stage I (BC I), BC IIA, BC IIB, and BC III in Korean women were measured using an enzyme-linked immunosorbent assay (ELISA). AGP was purified from individual sera by hot phenol extraction and then subjected to AGP glycosylation analysis. Three types of AGP glycosylation (fucosylation, high-mannose-type and sialylation) were detected using enzyme-linked lectin assays (ELLAs). Serum AGP levels were higher in BC I, BC IIA, BC IIB, and BC III, than in the BN group, and the level in BC I and BC IIA was high enough to be distinguished from BN. Meanwhile, terminal fucosylation and high-mannose-type glycans appeared to be lowest in BC I. The glycosylation levels of BC I provide sensitivity and specificity that make BC I clearly distinguishable from BC IIA, BC IIB, and BC III as well as BN. Therefore, determination of serum AGP or AGP glycosylation level could be useful for detecting the early stages of breast cancer.

Keywords

References

  1. Heegaard PM, Miller I, Sorensen NS, Soerensen KE, Skovgaard K. 2013. Pig alpha1-acid glycoprotein: characterization and first description in any species as a negative acute phase protein. PLoS One 8: e68110. https://doi.org/10.1371/journal.pone.0068110
  2. Schmid K, Nimerg RB, Kimura A, Yamaguchi H, Binette JP. 1977. The carbohydrate units of human plasma alpha1-acid glycoprotein. Biochim. Biophys. Acta 492: 291-302. https://doi.org/10.1016/0005-2795(77)90080-0
  3. Hochepied T, Berger FG, Baumann H, Libert C. 2003. Alpha(1)-acid glycoprotein: an acute phase protein with inflammatory and immunomodulating properties. Cytokine Growth Factor Rev. 14: 25-34. https://doi.org/10.1016/S1359-6101(02)00054-0
  4. Bteich M. 2019. An overview of albumin and alpha-1-acid glycoprotein main characteristics: highlighting the roles of amino acids in binding kinetics and molecular interactions. Heliyon 5: e02879. https://doi.org/10.1016/j.heliyon.2019.e02879
  5. Kwon H, Pessin JE. 2013. Adipokines mediate inflammation and insulin resistance. Front. Endocrinol. (Lausanne) 4: 71.
  6. Lumeng CN, Saltiel AR. 2011. Inflammatory links between obesity and metabolic disease. J. Clin. Invest. 121: 2111-2117. https://doi.org/10.1172/JCI57132
  7. Bachtiar I, Santoso JM, Atmanegara B, Gani RA, Hasan I, Lesmana LA, et al. 2009. Combination of alpha-1-acid glycoprotein and alpha-fetoprotein as an improved diagnostic tool for hepatocellular carcinoma. Clin. Chim. Acta 399: 97-101. https://doi.org/10.1016/j.cca.2008.09.024
  8. Ohbatake Y, Fushida S, Tsukada T, Kinoshita J, Oyama K, Hayashi H, et al. 2016. Elevated alpha1-acid glycoprotein in gastric cancer patients inhibits the anticancer effects of paclitaxel, effects restored by co-administration of erythromycin. Clin. Exp. Med. 16: 585-592. https://doi.org/10.1007/s10238-015-0387-9
  9. Katnik I, Gerber J, Dobryszycka W. 1988. Microheterogeneity of alpha 1-acid glycoprotein in the sera of patients with cancer or inflammatory states of the ovaries. Arch. Immunol. Ther. Exp. (Warsz) 36: 1-6.
  10. Piver MS, Moyer M, Diakun K, Lele SB, Chu TM. 1988. Serum alpha 1-acid glycoprotein in epithelial ovarian cancer. Gynecol. Oncol. 29: 305-308. https://doi.org/10.1016/0090-8258(88)90229-6
  11. Fernandes CL, Ligabue-Braun R, Verli H. 2015. Structural glycobiology of human alpha1-acid glycoprotein and its implications for pharmacokinetics and inflammation. Glycobiology 25: 1125-1133. https://doi.org/10.1093/glycob/cwv041
  12. Nakano M, Kakehi K, Tsai MH, Lee YC. 2004. Detailed structural features of glycan chains derived from alpha1-acid glycoproteins of several different animals: the presence of hypersialylated, O-acetylated sialic acids but not disialyl residues. Glycobiology 14: 431-441. https://doi.org/10.1093/glycob/cwh034
  13. Zhang D, Huang J, Luo D, Feng X, Liu Y, Liu Y. 2017. Glycosylation change of alpha-1-acid glycoprotein as a serum biomarker for hepatocellular carcinoma and cirrhosis. Biomark. Med. 11: 423-430. https://doi.org/10.2217/bmm-2016-0284
  14. Hashimoto S, Asao T, Takahashi J, Yagihashi Y, Nishimura T, Saniabadi AR, et al. 2004. alpha1-acid glycoprotein fucosylation as a marker of carcinoma progression and prognosis. Cancer 101: 2825-2836. https://doi.org/10.1002/cncr.20713
  15. Balmana M, Gimenez E, Puerta A, Llop E, Figueras J, Fort E, et al. 2016. Increased alpha1-3 fucosylation of alpha-1-acid glycoprotein (AGP) in pancreatic cancer. J. Proteomics 132: 144-154. https://doi.org/10.1016/j.jprot.2015.11.006
  16. Yazawa S, Takahashi R, Yokobori T, Sano R, Mogi A, Saniabadi AR, et al. 2016. Fucosylated glycans in alpha1-acid glycoprotein for monitoring treatment outcomes and prognosis of cancer patients. PLoS One 11: e0156277. https://doi.org/10.1371/journal.pone.0156277
  17. Organization WH. 2019. Breast cancer. https://www.who.int/cancer/prevention/diagnosis-screening/breast-cancer/en/.
  18. Youlden DR, Cramb SM, Yip CH, Baade PD. 2014. Incidence and mortality of female breast cancer in the Asia-Pacific region. Cancer Biol. Med. 11: 101-115.
  19. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. 2007. American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 25: 5287-5312. https://doi.org/10.1200/JCO.2007.14.2364
  20. Saldova R, Asadi Shehni A, Haakensen VD, Steinfeld I, Hilliard M, Kifer I, et al. 2014. Association of N-glycosylation with breast carcinoma and systemic features using high-resolution quantitative UPLC. J. Proteome Res. 13: 2314-2327. https://doi.org/10.1021/pr401092y
  21. Chan J, Yu D. 1991. One-step isolation of alpha 1-acid glycoprotein. Protein Exp. Purif. 2: 34-36. https://doi.org/10.1016/1046-5928(91)90006-5
  22. Kim HJ, Lim SJ, Kwag HL, Kim HJ. 2012. The choice of resin-bound ligand affects the structure and immunogenicity of column-purified human papillomavirus type 16 virus-like particles. PLoS One 7: e35893. https://doi.org/10.1371/journal.pone.0035893
  23. Park MH, You JW, Kim HJ, Kim HJ. 2019. IgG and IgM responses to human papillomavirus L1 virus-like particle as a function of dosing schedule and vaccine formulation. J. Microbiol. 57: 821-827. https://doi.org/10.1007/s12275-019-9308-z
  24. Giuliano AE, Connolly JL, Edge SB, Mittendorf EA, Rugo HS, Solin LJ, et al. 2017. Breast cancer-major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA. Cancer J. Clin. 67: 290-303. https://doi.org/10.3322/caac.21393
  25. Durham M, Regnier FE. 2006. Targeted glycoproteomics: serial lectin affinity chromatography in the selection of O-glycosylation sites on proteins from the human blood proteome. J. Chromatogr. A. 1132: 165-173. https://doi.org/10.1016/j.chroma.2006.07.070
  26. Choi JW, Moon BI, Lee JW, Kim HJ, Jin Y, Kim HJ. 2018. Use of CA153 for screening breast cancer: An antibodylectin sandwich assay for detecting glycosylation of CA153 in sera. Oncol. Rep. 40: 145-154.
  27. Stowell SR, Ju T, Cummings RD. 2015. Protein glycosylation in cancer. Annu. Rev. Pathol. 10: 473-510. https://doi.org/10.1146/annurev-pathol-012414-040438
  28. Hulsmeier AJ, Paesold-Burda P, Hennet T. 2007. N-glycosylation site occupancy in serum glycoproteins using multiple reaction monitoring liquid chromatography-mass spectrometry. Mol. Cell Proteomics 6: 2132-2138. https://doi.org/10.1074/mcp.M700361-MCP200
  29. Lee CS, Taib NA, Ashrafzadeh A, Fadzli F, Harun F, Rahmat K, et al. 2016. Unmasking heavily O-Glycosylated serum proteins using perchloric acid: identification of serum proteoglycan 4 and protease C1 inhibitor as molecular indicators for screening of breast cancer. PLoS One 11: e0149551. https://doi.org/10.1371/journal.pone.0149551
  30. Kremer JM, Wilting J, Janssen LH. 1988. Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol. Rev. 40: 1-47.
  31. McCurdy TR, Bhakta V, Eltringham-Smith LJ, Gataiance S, Fox-Robichaud AE, Sheffield WP. 2011. Comparison of methods for the purification of alpha-1 acid glycoprotein from human plasma. J. Biomed. Biotechnol. 2011: 578207.
  32. Mackiewicz A, Mackiewicz K. 1995. Glycoforms of serum alpha 1-acid glycoprotein as markers of inflammation and cancer. Glycoconj. J. 12: 241-247. https://doi.org/10.1007/BF00731326
  33. Pos O, Oostendorp RA, van der Stelt ME, Scheper RJ, Van Dijk W. 1990. Con A-nonreactive human alpha 1-acid glycoprotein (AGP) is more effective in modulation of lymphocyte proliferation than Con A-reactive AGP serum variants. Inflammation 14: 133-141. https://doi.org/10.1007/BF00917452
  34. Shiyan SD, Bovin NV. 1997. Carbohydrate composition and immunomodulatory activity of different glycoforms of alpha1-acid glycoprotein. Glycoconj. J. 14: 631-638. https://doi.org/10.1023/A:1018544711767
  35. Bories PN, Guenounou M, Feger J, Kodari E, Agneray J, Durand G. 1987. Human alpha 1-acid glycoprotein-exposed macrophages release interleukin 1 inhibitory activity. Biochem. Biophys. Res. Commun. 147: 710-715. https://doi.org/10.1016/0006-291X(87)90988-0

Cited by

  1. Orosomucoid 1 promotes epirubicin resistance in breast cancer by upregulating the expression of matrix metalloproteinases 2 and 9 vol.12, pp.1, 2021, https://doi.org/10.1080/21655979.2021.1987067
  2. Breast cancer glycan biomarkers: their link to tumour cell metabolism and their perspectives in clinical practice vol.18, pp.10, 2020, https://doi.org/10.1080/14789450.2021.1996231